The Quantellect read.As of Nov 19, 2026, 4 active firms cover Microbot Medical Inc: 4 rate it Buy or better, 0 sit at Neutral, and 0 rate it Sell or worse, a buy consensus. The target range is very wide, $4.00 to $12.00 (about 3.0x), which points to deep disagreement over how to value the company rather than near-term timing. The average target of $6.38 sits 778% above the current $0.73. The rating mix has held broadly steady over recent months. On the fundamentals, the Street sees consensus EPS building from about $-0.08 next quarter toward $-0.32 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS4 active firms
Buy
Strong Buy00%
Buy4100%
Neutral00%
Sell00%
Strong Sell00%
Based on 4 active firms as of Nov 19, 2026 (365-day activity window).
12-MONTH PRICE TARGET
$6.38
+778.5% upside
Average target across 4 active firms as of Nov 19, 2026 vs $0.73 current
Highest Target$12.00
Average Target$6.38
Lowest Target$4.00
Detailed analyst forecasts for MBOT
Showing 1–4 of 4 named analysts shown · 4 active firms in the rating projection
As of Nov 19, 2026, 4 of 4 active firms rate MBOT a Buy (0 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
MBOT EPS & revenue forecast
EPS · NEXT QUARTER
$-0.08
Range $-0.09 – $-0.07 · 3 analysts · +60% YoY
Next period, 3 analysts expect Microbot Medical Inc to earn $-0.08 a share (range $-0.09 – $-0.07), versus $-0.05 a year earlier. Full-year consensus is $-0.30, growing to $-0.32 the year after.
REVENUE · NEXT QUARTER
$666.7K
Range $400.0K – $900.0K · 3 analysts · +535% YoY
Revenue is expected to reach $666.7K (range $400.0K – $900.0K), +534.9% year-over-year. Full-year consensus is $1.3M, rising to $6.1M next year.
Top analysts covering Microbot Medical Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on MBOT.
#1
Raghuram Selvaraju
HC Wainwright & Co. · Rank #423
Buy
$12.00+1553.6% to target
Overall win rate
36%
+ Follow
#2
AS
Anderson Schock
B. Riley Securities
Buy
$4.00+451.2% to target
Coverage
—
+ Follow
#3
KB
Kyle Bauser
Roth Capital
Buy
$5.50+657.9% to target
Coverage
—
+ Follow
MBOT stock forecast FAQ
What is MBOT's average 12-month price target?+
The 4 active firms with a live target average $6.38 for Microbot Medical Inc over the next 12 months, ranging from a $12.00 high to a $4.00 low, as of Nov 19, 2026.
Is MBOT stock a Buy, Sell or Neutral right now?+
The current consensus is Buy. Of the 4 active firms as of Nov 19, 2026, 4 rate it Buy or Strong Buy, 0 rate it Neutral, and 0 rate it Sell or Strong Sell.
What are the highest and lowest price targets for MBOT?+
The Street-high target is $12.00 (HC Wainwright & Co.), and the Street-low is $4.00 (B. Riley Securities). The average of all 4 active-firm targets is $6.38.
How many active Wall Street firms cover MBOT?+
4 active firms have a recognized rating on Microbot Medical Inc as of Nov 19, 2026, and 4 active firms carry a live 12-month price target.
Who is the most accurate analyst covering MBOT?+
Among analysts who currently cover MBOT, Raghuram Selvaraju of HC Wainwright & Co. has the strongest overall Quantellect track record (Rank #423). Their current call is Buy with a $12.00 target.
What is Microbot Medical Inc's projected EPS for next quarter?+
The consensus estimate is $-0.08 per share (range $-0.09 – $-0.07) across 3 analysts. Full-year EPS is projected at $-0.30, rising to $-0.32 the following year.
How much revenue is Microbot Medical Inc expected to report next quarter?+
Consensus revenue is $666.7K (range $400.0K – $900.0K). Full-year revenue is projected at $1.3M, growing to $6.1M next year.
Have analysts been upgrading or downgrading MBOT lately?+
As of Nov 19, 2026, 4 of 4 active firms rate MBOT a Buy (0 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their MBOT calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.